Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

Allergan and Ironwood are going where GI commercials have not gone before: into the bathroom. A new TV ad for Linzess, begun last week, features two different people sitting on the toilet—viewers see ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for this condition in younger patients. This medication helps improve bowel ...

There’s a new competitor to Allergan and Ironwood’s Linzess on the block in the chronic idiopathic constipation (CIC) market. And the way some industry watchers see it, it may not be long before the ...

Linzess (linaclotide), a medication for irritable bowel syndrome (IBS) with constipation or chronic idiopathic constipation is now available in American pharmacies, Ironwood Pharmaceuticals Inc. and ...

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.

Tablets explicitly designed for weight reduction might be an excellent choice for those who want to get rid of excess weight in a hurry without having to make significant changes to their eating ...